Clinical Trials on Lung Non-Small Cell Carcinoma

Total 18438 results

National Cancer Institute (NCI)

Completed

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Peking University People's Hospital
National Natural Science Foundation of China

Completed

Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients

Carcinoma | Lung Neoplasms | Non-small-cell Lung Cancer

China
Eckhard Podack

Withdrawn

Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Non-small-cell Lung Carcinoma
Francisco Robert,MD
Sanofi; Bayer

Terminated

Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

Non Small Cell Lung Cancer | Non Squamous Cell Lung Cancer

United States
Shenzhen TargetRx, Inc.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...

Recruiting

TGRX-326 Pharmacokinetic Drug Interaction

Non Small Cell Lung Cancer

China
University of Utah

Recruiting

Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE)

Non Small Cell Lung Cancer

United States
Sun Yat-sen University

Recruiting

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Non-small Cell Lung Cancer

China
Quanli Gao

Recruiting

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

Non-small Cell Lung Cancer

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status. (TEMPLE-2)

Non Small Cell Lung Cancer

Italy
Shanghai Henlius Biotech

Recruiting

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer

China
RedCloud Bio
R&G Pharma Studies Co.,Ltd.

Recruiting

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
RedCloud Bio
Parexel

Recruiting

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Non-small Cell Lung Cancer

United States
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Non-small Cell Lung Cancer

China
Fudan University
Allist Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Non-Small-Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (SACHI)

Non-small Cell Lung Cancer

China
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (FLAME)

Non Small Cell Lung Cancer

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

Non Small Cell Lung Cancer

China
Guangzhou Institute of Respiratory Disease
Tongji Hospital; Shenzhen People's Hospital

Recruiting

Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia

Non Small Cell Lung Cancer

China
Pfizer

Recruiting

Safety and Efficacy of Xalkori ROS1

Non-small Cell Lung Cancer

Japan
Shaare Zedek Medical Center
AstraZeneca

Recruiting

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Lung Cancer, Non-small Cell

Israel
Hoffmann-La Roche

Active, not recruiting

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung

United States, Korea, Republic of, United Kingdom, Australia, France, Italy, Spain, Japan, Brazil, China, Germany, Poland, Thailand, Israel, Switzerland, Taiwan, Austria, Russian Federation, Ukraine, Hungary, Serbia, Slovenia, South... and more
Lawson Health Research Institute

Active, not recruiting

SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial

Non Small Cell Lung Cancer

Canada
Novartis Pharmaceuticals

Active, not recruiting

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N)

Non-small Cell Lung Cancer

United States
Amgen

Active, not recruiting

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (CodeBreaK201)

Non-small Cell Lung Cancer

Belgium, Spain, United States, Denmark, Sweden, France, Turkey, Italy, Germany, Netherlands
Canadian Cancer Trials Group
AstraZeneca

Completed

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

Non Small Cell Lung Cancer

Canada
University Health Network, Toronto

Completed

Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study (VALUE)

Non-small Cell Lung Cancer

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Non Small Cell Lung Cancer

China
AstraZeneca
Quintiles, Inc.

Completed

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Spain, France
Novartis Pharmaceuticals

Terminated

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Non-small Cell Lung Cancer

France, Spain, United States, Belgium, Netherlands, Canada, Italy, Singapore, Korea, Republic of, Czechia, Germany, Hong Kong
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Non-small Cell Lung Cancer

China
AstraZeneca

Completed

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Non-small Cell Lung Cancer

China
Hanmi Pharmaceutical Company Limited

Terminated

Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

Non Small Cell Lung Cancer

Korea, Republic of
The First Hospital of Jilin University

Unknown

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Non Small Cell Lung Cancer

China
Massachusetts General Hospital
National Comprehensive Cancer Network

Unknown

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Non Small Cell Lung Cancer

United States
Konkuk University Medical Center
Hanmi Pharmaceutical Company Limited

Completed

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Non Small Cell Lung Cancer

Korea, Republic of
Carevive Systems, Inc.

Completed

Understanding Evidence-Based Practice Patterns in Advanced NSCLC

Non Small Cell Lung Cancer

United States
Yong Fang
Zhejiang Cancer Hospital; Zhejiang Provincial People's Hospital; Ningbo No. 1... and other collaborators

Unknown

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (ACWDVDFPTAN)

Non-small Cell Lung Cancer

China
AstraZeneca

Completed

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Non Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, Canada, Brazil, Hungary, Peru, Czechia, Bulgaria, Mexico
Hanmi Pharmaceutical Company Limited

Completed

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Non Small Cell Lung Cancer

Korea, Republic of
Ethicon Endo-Surgery

Completed

Powered Surgical Stapler in VATS Lung Resection Procedures in China

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Non Small Cell Lung

China
The Catholic University of Korea

Unknown

Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment (ANKL-2)

Non-small Cell Lung Cancer

Korea, Republic of
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Completed

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients (GEFTREM)

Non Small Cell Lung Cancer

France
Fudan University

Unknown

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Non Small Cell Lung Cancer

China
Maastricht Radiation Oncology
University of Pennsylvania

Completed

State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients (Lung stage I)

Non Small Cell Lung Cancer

Netherlands
AstraZeneca
Parexel

Withdrawn

T790M Mutation Positive 2nd Line STandard of cAre Registry (T-STAR)

Non Small Cell Lung Cancer

Italy, Russian Federation, Spain, China, Netherlands, United States, Taiwan, France, Germany

Clinical Trials on Lung Non-Small Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations